OR WAIT null SECS
© 2021 MJH Life Sciences and BioPharm International. All rights reserved.
© 2021 MJH Life Sciences™ and BioPharm International. All rights reserved.
Single-use technologies allowed drug manufacturers to adapt to pandemic challenges.
Help prevent contamination in each of seven facility zones.
October 08, 2021
Pfizer may pay up to $630 million for access to Voyager’s novel AAV capsids in transgene research.
Moderna’s new facility is expected to produce 500 million vaccine doses per year.
October 07, 2021
The $3 million investment will go towards various projects investigating key product attributes for therapeutic proteins.
October 06, 2021
New excipients for protein-based drug products reduce viscosity while maintaining protein stability.
October 04, 2021
Thermo Fisher’s new Swiss facility will initially produce CSL Limited’s recombinant factor IX product Idelvion.
October 02, 2021
The complexity of newer biotherapeutic molecules calls for alternative drug delivery strategies.
The intranasal route of administration is showing clinical promise, particularly for COVID-19, but there are multiple hurdles to overcome to ensure successful formulation.
Large-scale single-use bioreactors prove successful as limits are tested.
October 01, 2021
SUB bioreactor performance has had seen its limits and successes.
Early control architecture decisions can impact a facility’s long-term growth, flexibility, and efficiency.